JP2010521483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521483A5 JP2010521483A5 JP2009553765A JP2009553765A JP2010521483A5 JP 2010521483 A5 JP2010521483 A5 JP 2010521483A5 JP 2009553765 A JP2009553765 A JP 2009553765A JP 2009553765 A JP2009553765 A JP 2009553765A JP 2010521483 A5 JP2010521483 A5 JP 2010521483A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hcv
- piperazinyl
- cycloalkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 47
- -1 N-alkylpiperazinyl Chemical group 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 125000004193 piperazinyl group Chemical group 0.000 claims 15
- 125000001475 halogen functional group Chemical group 0.000 claims 14
- 125000003386 piperidinyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 12
- 125000002757 morpholinyl group Chemical group 0.000 claims 11
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229940121649 protein inhibitor Drugs 0.000 claims 5
- 239000012268 protein inhibitor Substances 0.000 claims 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 229940122750 HCV entry inhibitor Drugs 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 125000005293 bicycloalkoxy group Chemical group 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- CRKULFPPCILKNJ-UHFFFAOYSA-N diazepan-3-one Chemical compound O=C1CCCCNN1 CRKULFPPCILKNJ-UHFFFAOYSA-N 0.000 claims 2
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 claims 2
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229940124683 HCV polymerase inhibitor Drugs 0.000 claims 1
- 229940121759 Helicase inhibitor Drugs 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488907P | 2007-03-14 | 2007-03-14 | |
| US98952207P | 2007-11-21 | 2007-11-21 | |
| PCT/US2008/056789 WO2008112851A1 (en) | 2007-03-14 | 2008-03-13 | Cyclopropyl fused indolobenzazepine hcv inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010521483A JP2010521483A (ja) | 2010-06-24 |
| JP2010521483A5 true JP2010521483A5 (enExample) | 2011-04-14 |
Family
ID=39541177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009553765A Pending JP2010521483A (ja) | 2007-03-14 | 2008-03-13 | シクロプロピル縮合インドロベンゾアゼピンｈｃｖインヒビター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7538102B2 (enExample) |
| EP (1) | EP2118110B1 (enExample) |
| JP (1) | JP2010521483A (enExample) |
| CN (1) | CN101790533B (enExample) |
| ES (1) | ES2390191T3 (enExample) |
| WO (1) | WO2008112851A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| CN101918410B (zh) * | 2007-11-20 | 2013-02-27 | 百时美施贵宝公司 | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| JP2011515496A (ja) | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| JP2011515486A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の治療用化合物 |
| CN102046630A (zh) * | 2008-03-27 | 2011-05-04 | 百时美施贵宝公司 | 吡咯烷稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂 |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN103649079B (zh) | 2010-12-22 | 2016-11-16 | Abbvie公司 | 丙型肝炎抑制剂及其用途 |
| CN102659668B (zh) * | 2012-05-03 | 2014-04-09 | 苏州汉德创宏生化科技有限公司 | 1-烷基-哌啶-4-磺酰苄胺的合成方法 |
| US9556204B2 (en) * | 2012-07-18 | 2017-01-31 | Bristol-Myers Squibb Company | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE428714T1 (de) | 2004-02-24 | 2009-05-15 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1807397A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| DE602007006796D1 (de) * | 2006-05-25 | 2010-07-08 | Bristol Myers Squibb Co | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer |
| US7521442B2 (en) * | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101679437B (zh) * | 2007-03-13 | 2013-04-17 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
-
2008
- 2008-03-11 US US12/046,030 patent/US7538102B2/en active Active
- 2008-03-13 CN CN2008800159152A patent/CN101790533B/zh not_active Expired - Fee Related
- 2008-03-13 EP EP08743824A patent/EP2118110B1/en not_active Not-in-force
- 2008-03-13 WO PCT/US2008/056789 patent/WO2008112851A1/en not_active Ceased
- 2008-03-13 JP JP2009553765A patent/JP2010521483A/ja active Pending
- 2008-03-13 ES ES08743824T patent/ES2390191T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010521483A5 (enExample) | ||
| JP2010521481A5 (enExample) | ||
| JP2010521484A5 (enExample) | ||
| JP2010515752A5 (enExample) | ||
| JP2010521476A5 (enExample) | ||
| JP2010521482A5 (enExample) | ||
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| JP2008530096A5 (enExample) | ||
| AR065772A1 (es) | Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2012504632A5 (enExample) | ||
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2010510234A5 (enExample) | ||
| MY146123A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| EP2374464A3 (en) | HCV N3S-NS4A protease inhibition | |
| JP2012512169A5 (enExample) | ||
| WO2005037860A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| MX2007004783A (es) | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. | |
| EP1615613A4 (en) | MACROCYCLIC QUINOXALINYL COMPOUNDS INHIBITING SERINE PROTEASES OF HEPATITIS C | |
| JP2011523651A5 (enExample) | ||
| JP2007535491A5 (enExample) | ||
| WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
| JP2014522809A5 (enExample) |